Xenon (XENE) CFO Kelly Thomas Patrick Buys 15,000 Shares

What Happened
Kelly Thomas Patrick, Chief Financial Officer of Xenon Pharmaceuticals, purchased 15,000 shares in an open-market transaction on September 30, 2026. The shares were acquired at $37.32 each, for a total transaction value of $559,740. This was a direct purchase (transaction code P), which investors often view as a more informative (potentially bullish) insider move than routine sales, though motivations are not disclosed.

Key Details

• Transaction date and price: 2026-09-30, 15,000 shares at $37.32 each.
• Total value: $559,740.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction type/code: Open-market purchase (P).
• Footnotes/notable plan info: None disclosed in the provided data (no 10b5-1 or tax-withholding notes provided).
• Filing timeliness: Report filed 2026-10-01 — within the standard Form 4 filing window (filed one day after the transaction).

Context
Open-market purchases are straightforward cash buys of company stock by insiders. While purchases can be interpreted as a sign that an insider chose to increase their stake, Form 4 disclosures are factual records and do not explain the insider’s reasons. Retail investors should consider this trade alongside company fundamentals and other insider activity.